DocGo reported its Q1 2023 results, highlighting continued operational execution and growth in the RFP channel. The company also signed agreements to expand its remote patient monitoring and chronic care management services.
Continued operational execution was achieved during the quarter.
The company experienced an increase in backlog.
Growth was seen in the company's RFP channel.
Agreements were signed to expand remote patient monitoring and chronic care management services.
DocGo reiterates its 2023 Revenue Guidance of $500-$510 million and Adjusted EBITDA Guidance of $45-$50 million.
Analyze how earnings announcements historically affect stock price performance